Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ezeprogind
- Development stage
- Phase 2
- Lead developer
- Alzprotect
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Ezeprogind (AZP2006) is an orally bioavailable small molecule neurotrophic inducer with potent neuroprotective properties. It acts primarily as a progranulin/prosaposin modulator, stabilizing the prosaposin-progranulin complex to increase levels of the neurotrophic factor progranulin in the brain. This mechanism promotes neuronal survival, enhances lysosomal function, reduces tau hyperphosphorylation, mitigates neuroinflammation by decreasing pro-inflammatory cytokines (such as IL‑1β and IL‑6), and supports synaptogenesis. Ezeprogind is being developed for progressive supranuclear palsy (PSP), a rare tauopathy, and has also been investigated for Alzheimer's disease and Parkinson's disease. The drug was developed by AlzProtect[1][2][4][5][6].
- Brand names
- Ezeprogind
- Other names
- AZP2006AZP-2006AZP 2006Ezeprogind disulfateAsp2006 free baseAsp-2006 free baseAsp 2006 free base
02
Targets
PSAP (Prosaposin–progranulin complex)
Beyond the preview
Go deeper on Ezeprogind.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ezeprogind.